Cost-effective diagnostics for cancer? Only with VolitionRx!

June 24, 2016 - 1 minute

Aberdeen, we say goodbye to you!

We’re leaving Scotland this week and are heading down to Belgium. Besides being the place where most of the European Union action happens, Belgium also has a strong and interesting biotech scene. That’s why in Namur we’re visiting VolitionRx, our Biotech of the Week.


City: Namur (Belgium)

Founded: 2010

Employees: 11-50 employees 

Content continues below

Related Content

Financial Data: €77M

CEO: Cameron Reynolds


Mission: VolitionRx wants to address the need for non-invasive, accurate, and cost-effective diagnostics for cancer and other conditions.

Founded in 2010, VolitionRx brings together ELISA diagnostics (a long established method to identify proteins) with cutting-edge nucleosome detection and analysis techniques.

The resulting test takes less than a drop of blood and can measure and analyze nucleosomes (a basic unit of ‘packed’ DNA), which are often irregular in diseases like cancer.

Content continues below

Related Content

Comment: The market cap of VolitionRx is over €78M, which is quite big for a diagnostics-focused biotech.

Blood-based diagnostics are a definite trend (see the discussion of Eva Diagnostics at Labiotech Refresh), and VolitionRx’s technology looks really exciting.

Feature Image Credit: Labiotech Map

You might also be interested in the following: